Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.51 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | ANPEP | P15144 | 2/20 | 0.50 |
| ▸ | PEPD | P12955 | 2/20 | 0.48 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ACE | P12821 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL468719 | 1.00 | POLB (0.58) | POLBFKBP1AMMP2ANPEPPEPD | |
| SCHEMBL14426613 | 1.00 | POLB (0.58) | POLBFKBP1AMMP2ANPEPPEPD | |
| SCHEMBL14426630 | 0.94 | FKBP1A (0.57) | POLBFKBP1AMMP2ANPEPPEPD | |
| SCHEMBL12566180 | 0.94 | FKBP1A (0.57) | POLBFKBP1AMMP2ANPEPPEPD | |
| SCHEMBL28530831 | 0.93 | FKBP1A (0.56) | POLBFKBP1AMMP2ANPEPPEPD | |
| SCHEMBL17464830 | 0.88 | MMP2 (0.53) | POLBFKBP1AMMP2ANPEPPEPD | |
| SCHEMBL2771429 | 0.88 | MMP2 (0.53) | POLBFKBP1AMMP2ANPEPPEPD | |
| SCHEMBL10143725 | 0.85 | POLB (0.55) | POLBFKBP1AMMP2ANPEPPEPD | |
| SCHEMBL9546469 | 0.85 | POLB (0.58) | POLBFKBP1APEPDXPNPEP1ALOX5 | |
| SCHEMBL9533366 | 0.85 | POLB (0.62) | POLBFKBP1AMMP2ANPEPPEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE42902-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2011-11-08 | — | — | US | claimed |
| US-RE41339-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2010-05-18 | — | — | US | claimed |
| WO-2006119283-A2 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J (US) | 2006-11-09 | — | — | WO | claimed |
| US-20060251597-A1 | ANTI-ODOR COMPOSITIONS AND THERAPEUTIC USE | YU RUEY J | 2006-11-09 | — | — | US | claimed |
| EP-3686201-A1 | INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019052565-A1 | INFLUENZA VIRUS REPLICATION INHIBITOR AND USE THEREOF | 广东东阳光药业有限公司 | 2019-03-21 | — | — | WO | disclosed |
| US-9493446-B2 | Orexin receptor antagonists which are [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]-methanone derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2016-11-15 | — | — | US | disclosed |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-10 | — | — | US | disclosed |
| US-8835428-B2 | Diacylglycerol acyltransferase inhibitors | Piramal Enterprises Limited (IN) | 2014-09-16 | — | — | US | disclosed |
| US-20130116284-A1 | LIPOIC ACID AND NITROXIDE DERIVATIVES AND USES THEREOF | RADIKAL THERAPEUTICS INC. (US) | 2013-05-09 | — | — | US | disclosed |
| EP-2390260-A2 | Ester derivative of ethinyl estradiol | Warner Chilcott Company, LLC (PR) | 2011-11-30 | — | — | EP | disclosed |
| US-20100256333-A1 | Peptide-Based Beta Turn Mimetics | UNIVERSITY OF MANITOBA (CA) | 2010-10-07 | — | — | US | disclosed |
| EP-0863883-A1 | ALPHA-(1,3-DICARBONYLENOL ETHER) METHYL KETONES AS CYSTEINE PROTEASE INHIBITORS | PROTOTEK, INC., (US) | 1998-09-16 | — | — | EP | disclosed |
| US-5714484-A | α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors | PROTOTEK, INC. (US) | 1998-02-03 | — | — | US | disclosed |
| WO-1996040647-A1 | α-(1,3-DICARBONYLENOL ETHER) METHYL KETONES AS CYSTEINE PROTEASE INHIBITORS | PROTOTEK, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0416282-B1 | Microbiologically produced N-Acyl-L-proline-acylase, process for its production and its use | DEGUSSA (DE) | 1994-09-14 | — | — | EP | disclosed |
| US-5219741-A | Reacting in the presence of microbiologically produced N-acyl-L-proline acylase | DEGUSSA AG (DE) | 1993-06-15 | — | — | US | disclosed |
| US-5120652-A | Synthesis of proline from acyl derivatives; thermostable | DEGUSSA AG (DE) | 1992-06-09 | — | — | US | disclosed |
| EP-0416282-A1 | Microbiologically produced N-Acyl-L-proline-acylase, process for its production and its use | Degussa Aktiengesellschaft (DE) | 1991-03-13 | — | — | EP | disclosed |
| US-4749786-A | α-amino acids through catalytic reaction of CO and a hydroxyl compound with enamides | THE STANDARD OIL COMPANY (US) | 1988-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256333-A1 | Peptide-Based Beta Turn Mimetics | VIP, PTMA, PREP | POLB 1057/4885FKBP1A 383/4885MMP2 2253/4885 |
| US-20150252032-A1 | OREXIN RECEPTOR ANTAGONISTS WHICH ARE [ORTHO BI-(HETERO-)ARYL]-[2-(META BI-(HETERO-)ARYL)-PYRROLIDIN-1-YL]-METHANONE DERIVATIVES | HCRTR2, HCRTR1, OXTR | POLB 3386/4885FKBP1A 598/4885MMP2 4096/4885 |
| US-20130116284-A1 | LIPOIC ACID AND NITROXIDE DERIVATIVES AND USES THEREOF | PARP1, PARP2, PARP6 | POLB 157/4885FKBP1A 1410/4885MMP2 1299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.